Drug or treatment

Surufatinib clinical trials

• 19Clinical trials
• 1Country

Newest trials

All recruiting trials (19)

• Hypofractionated chemoradiotherapy with tislelizumab and surufatinib for unresectable stage III NSCLC

  This phase 2 trial tests whether adding tislelizumab and surufatinib to hypofractionated chemoradiotherapy helps patients with unresectable stage III NSCLC, compared to tislelizumab alone after radiotherapy.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07609121

• Short-course radiotherapy then CapeOX and toripalimab, with or without surufatinib, before surgery for high-risk mid-to-low rectal cancer

  This trial tests whether adding surufatinib to short-course radiotherapy followed by CapeOX chemotherapy plus toripalimab before surgery improves tumor response in adults with high-risk mid-to-low rectal cancer.

  Recruiting Phase 2/3 The First Hospital of Jilin University · Changchun, Jilin · NCT07505472

• Surufatinib with Gemcitabine and Nab-paclitaxel as Neoadjuvant Therapy for High-Risk or Borderline Resectable Pancreatic Cancer

  This trial tests whether adding surufatinib to gemcitabine and nab-paclitaxel before surgery helps adults with high-risk resectable or borderline resectable pancreatic cancer.

  Recruiting Phase 3 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07436741

• Surufatinib plus chemotherapy versus surufatinib alone for pulmonary neuroendocrine tumors

  This trial will test whether adding chemotherapy to surufatinib helps people with pulmonary neuroendocrine tumors get better tumor responses or live longer and whether the combination is safe.

  Recruiting Phase 2 Shanghai Chest Hospital · Hefei, Anhui and 3 other locations · NCT07357623

• Surufatinib for adults with advanced neuroendocrine neoplasms in routine care

  This study will see if daily oral surufatinib, given alone or with other treatments, helps adults with advanced neuroendocrine tumors when used in regular clinical practice.

  Recruiting at 4 sites Phase 4 Shanghai Zhongshan Hospital · Shanghai and 3 other locations · NCT07272512

• Surufatinib with chemo-immunotherapy and chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma

  This trial will test whether adding surufatinib to two cycles of chemo-immunotherapy followed by concurrent chemoradiotherapy helps people with unresectable, locally advanced esophageal squamous cell carcinoma.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07086469

• Concurrent chemoradiotherapy with surufatinib and tislelizumab for unresectable stage III non-small cell lung cancer

  This tests whether adding surufatinib and tislelizumab to standard concurrent chemoradiotherapy, followed by continuing both drugs as consolidation, helps people with unresectable stage III non-small cell lung cancer.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07086456

• Combination treatment for recurrent head and neck cancer

  This study is testing a new combination of two drugs, Surufatinib and Envolizumab, to see if they can help people with recurrent head and neck cancer feel better when other treatments haven't worked.

  Recruiting Phase 2 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai · NCT06876844

• Combining chemotherapy and immunotherapy for limited-stage small cell lung cancer

  This study is testing a new treatment that combines chemotherapy and immunotherapy to see if it can help people with limited-stage small cell lung cancer live longer and feel better.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06719700

• Combining Surufatinib with Gemcitabine, Cisplatin, and Durvalumab/Pembrolizumab for Advanced Biliary Tract Cancer

  This study is testing if adding a new drug called surufatinib to the standard treatment for advanced biliary tract cancer can help patients live longer and feel better.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT06708858

• Combining Surufatinib with Chemotherapy for High-risk Ovarian Cancer

  This study is testing if a new drug called Surufatinib, when combined with standard chemotherapy and another medication, can help people with newly diagnosed high-risk ovarian cancer live longer and feel better.

  Recruiting Phase 2 Anhui Provincial Cancer Hospital · Hefei, Anhui · NCT06437353

• Evaluating a new treatment combination for metastatic pancreatic cancer

  This study is testing a new combination of treatments for people with advanced pancreatic cancer to see if it works better than the standard care they usually receive.

  Recruiting at 52 sites Phase 2/3 Hutchmed · Hefei, Anhui and 51 other locations · NCT06361888

• Combining Surufatinib with Temozolomide and S-1 for treating advanced neuroendocrine tumors

  This study is testing a new combination of three medications to see if it can help people with advanced neuroendocrine tumors who haven't had treatment before.

  Recruiting Phase 1/2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT06038461

• Surufatinib plus gemcitabine/nab‑paclitaxel versus gemcitabine/nab‑paclitaxel for first‑line advanced or metastatic pancreatic cancer

  This study will test whether adding surufatinib to standard gemcitabine plus nab‑paclitaxel helps people with locally advanced or metastatic pancreatic cancer who had two cycles of AG without disease progression.

  Recruiting Phase 2 Fudan University · Shanghai · NCT05969171

• Combining radiotherapy with Surufatinib and Sintilimab for high-risk localized soft tissue sarcoma

  This study is testing a new treatment that combines radiotherapy with two medications, Surufatinib and Sintilimab, to see if it can help people with high-risk localized soft tissue sarcoma.

  Recruiting Phase 1/2 Fudan University · Shanghai, Shanghai Municipality · NCT05839275

• Surufatinib and Serplulimab with Platinum/Etoposide for Neuroendocrine Carcinoma

  This study tests a combination of targeted therapy, immunotherapy, and chemotherapy in adults with newly treated neuroendocrine carcinoma to see if the regimen is safe and helps shrink tumors.

  Recruiting Phase 1/2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT05747729

• Combination treatment for metastatic adenocarcinoma of the small intestine or appendix

  This study is testing a new combination of three medications to see if they can help people with advanced cancer of the small intestine or appendix who haven't responded to other treatments.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT05472948

• Combining surufatinib and camrelizumab with chemotherapy for advanced pancreatic cancer

  This study is testing a new combination of treatments for people with advanced pancreatic cancer to see if it works better than the standard options.

  Recruiting Phase 1/2 Chinese PLA General Hospital · Beijing · NCT05218889

• Combination therapy for advanced high-grade neuroendocrine neoplasms

  This study is testing a new combination of three treatments to see if they can help people with advanced high-grade neuroendocrine tumors who haven't had success with standard therapies.

  Recruiting at 2 sites Phase 2 Peking University · Beijing, Beijing Municipality and 1 other locations · NCT05165407

Quick answers

How many clinical trials of Surufatinib are recruiting right now?

19, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 11, Phase 1/2: 4, Phase 2/3: 2, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →